CIRCULATING ACYLCARNITINES ARE ASSOCIATED WITH HEART FAILURE PROGRESSION: TIME FOR A NEW PARADIGM TOWARDS PERSONALIZED TIMING OF ADVANCED THERAPIES

Advanced heart failure (HF) is morbid and costly with 700,000 patients estimated to reach end-stage HF and be considered for ventricular assist device (VAD) or heart transplantation (HT). The transition to VAD or HT is informed by functional class, exercise capacity, and markers of end-organ